The Oak Ridge National Laboratory (ORNL) is recognized for its leadership in the development of advanced radiotherapies, particularly in the area of targeted alpha therapy.
Under the direction of Karen Sikes, the National Isotope Development Center at ORNL provides access to over 300 radioisotopes, essential for the implementation of these therapies.
This initiative aims to unify cancer care by leveraging specific isotopes to enhance treatment efficacy and patient outcomes, marking a significant advancement in oncological approaches.